Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Respiratory Aspiration 1Lymphoma, Follicular 1COVID-19 1

Interventions

COVID-19 Vaccines 4Blood Specimen Collection 4Surveys and Questionnaires 3Standard of Care 32019-nCoV Vaccine mRNA-1273 3Pandemic Preparedness 2sotrovimab 1sinovac COVID-19 vaccine 1selinexor 1regorafenib 1proxalutamide 1monalizumab 1lenzilumab 1ciclesonide 1bemcentinib 1avdoralimab 1acalabrutinib 1XAV-19 1Surgical Procedures, Operative 1Sperm Count 1Specimen Handling 1Sorafenib 1Sodium Chloride 1Rabeprazole 1Patient Reported Outcome Measures 1Observation 1Nutritional Status 1Niclosamide 1Meopa 1Mastectomy, Segmental 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × COVID-19 × IBIO123 × Clear all
NCT05303376 2023-09-13

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

Immune Biosolutions Inc

Phase 1/2 Completed
123 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular, Respiratory Aspiration

Data powered by HemOnc (CC BY 4.0) Colophon âš¡